Harrington Heart & Vascular Institute

Thursday, January 12, 2017

Harrington Discovery Institute announces 2016 Partnership Scholars

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has announced its 2016 partnership Scholars selected in collaboration with Alzheimer’s Drug Discovery Foundation (ADDF), and Foundation Fighting Blindness and University of Oxford.
Harrington Discovery Institute collaborations are based on a shared mission to advance discoveries into new medicines that will improve human health, as well as, enhance each organization's ability to play a significant role in setting the scientific and innovation agenda in leading-edge research.  These awards offer selected winners funding and expert pharmaceutical guidance to move their discoveries forward and ensure the most promising enter the clinic. Please join us in congratulating our newest scholars.
The 2016 ADDF-Harrington Scholars are: 
·         Travis Dunckley, PhD, Arizona State University, whose work focuses on using DYRK1A inhibitors to prevent cognitive impairment and Alzheimer’s pathology
·         Sung Ok Yoon, PhD, The Ohio State University, whose work focuses on using novel inhibitors of a stress-activated kinase for the treatment of Alzheimer’s disease
The 2016 Gund-Harrington Scholar is:
  • David M. Gamm, MD, PhD, University of Wisconsin-Madison, whose work focuses on restoring sight through the use of human pluripotent stem cells in individuals suffering from retinal degenerative disease
The 2016 Oxford-Harrington Scholar is: 
  • Valentine M. Macaulay, MD, PhD, whose work focuses on disrupting receptor internalization and nuclear translocation as a novel therapy for cancer
“The Cleveland-based Harrington Discovery Institute currently supports promising discoveries in North America and the U.K.,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute. “Our collaborations with disease foundations and like-minded research institutions allow us to better address underserved areas of medicine and to bring forth new medicines where treatments remain elusive.”    
“We at the Foundation Fighting Blindness continue to applaud Ron Harrington’s support for accelerating promising research from the bench to clinical studies,” said Gordon Gund, chairman and co-founder of the Foundation Fighting Blindness. “The Harrington Discovery Institute offers highly pragmatic support to our researchers, based in hundreds of years of collective experience from an impressive cadre of pharmaceutical R&D executives. Together we are dedicated to helping millions defeat diseases that limit the ability to experience the gift of sight.”
In addition to funding, award recipients receive committed drug development and project management support through the Harrington Discovery Institute’s Innovation Support Center for the duration of the term of the award. This includes consulting and management services from experienced pharmaceutical development professionals, as well as regulatory, intellectual property and business development assistance. 
“I am delighted that Professor Macaulay has been selected as the next Oxford-Harrington Scholar,” said Professor Sir John Bell, Regius Professor of Medicine, University of Oxford. “This program will support her novel approach around hormone receptors, which shows promise in treating cancers that touch millions of lives around the world.”
Harrington Scho

Tuesday, January 10, 2017

Harrington Discovery Institute and Alzheimer’s Drug Discovery Foundation expand collaboration

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the Alzheimer’s Drug Discovery Foundation (ADDF) have expanded their collaboration to accelerate translation of innovative research efforts for Alzheimer’s disease. Together, the two organizations will jointly market and administer a new award program for academic researchers. By leveraging their combined expertise, investment, and resources, Harrington Discovery Institute and the ADDF will advance Alzheimer’s disease drug discovery projects of great promise in academic institutions nationwide.
“We are so pleased to enhance our partnership with the ADDF and further support groundbreaking Alzheimer’s disease research,” commented Dr. Jonathan Stamler, MD, President, Harrington Discovery Institute. “Millions of patients and families in the US and around the world are eager for effective treatments. The ADDF has shown a sense of urgency that has made us a better organization, and we share their commitment to advancing neurological discoveries of great promise.”  
The keystone of the collaboration is the ADDF-Harrington Scholar Award, which provides funding and drug development support to both MD and PhD scientists across the United States, to help advance discovery into the clinical realm. In addition to financial support of up to $600,000, ADDF-Harrington Scholars also receive hands-on direction from pharmaceutical industry leaders in Harrington Discovery Institute’s Innovation Support Center, who have extensive experience bringing research to the market. ADDF-Harrington Scholars also have facilitated access to BioMotiv, the mission-driven development company associated with The Harrington Project.

Friday, January 06, 2017

Most younger adults with high LDL-C levels do not take a statin

CLEVELAND – Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a statin, according to a study published online by JAMA Cardiology.
Cardiovascular disease affects 1 in 3 patients and remains the leading cause of death in the United States. Severe elevation of LDL-C levels is a modifiable risk factor for developing premature cardiovascular disease. Treatment with statins is recommended for all adults 21 years or older with an LDL-C of 190 mg/dL or greater, with treatment appearing to reduce the risk of death and result in cost savings for health systems.

Tuesday, December 13, 2016

Harrington Discovery Institute at University Hospitals announces inaugural class of Cleveland Harrington Fellows

CLEVELAND – 2016 Harrington Fellows have been selected by Harrington Discovery Institute. The new Harrington Fellows Award recognizes promising early- to mid-career physician-scientists in the greater Cleveland medical community and provides $75,000 per year for two years to support their research efforts.
Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling the nation’s most inventive physician-scientists to turn their discoveries into medicines that improve human health.
The 2016 Harrington Fellows are:

Derek Abbott, MD, PhD, Associate Professor and Arline H. and Curtis F. Garvin Professor of Medicine and Co-Director, Medical Scientist Training Program, Case Western Reserve University School of Medicine. Dr. Abbott’s research has combined molecular, bioinformatics and proteomic approaches to identify and pharmaceutically target novel inflammatory signaling pathways. 

Alex Huang, MD, PhD, Associate Professor, Case Western Reserve University School of Medicine and Program Director, Pediatric Hematology and Oncology, UH Cleveland Medical Center. Dr. Huang’s research is focused on understanding cancer immunology and defining the cellular and molecular immunological principles governing tumor immunity to advance the application of cancer immunotherapy.

Nima Sharifi, MD, Kendrick Family Endowed Chair for Prostate Cancer Research, Cleveland Clinic Lerner Research Institute and Co-Director of the Prostate Cancer Research Center of Excellence at Cleveland Clinic. Dr. Sharifi’s research is centered on investigating metabolic and molecular mechanisms of hormone therapy resistance in prostate cancer and the development of new treatment strategies.
“We are pleased to support the research efforts of these three talented physician-scientists,” said Jonathan Stamler, MD, President of Harrington Discovery Institute, who also is Director of the Institute for Transformative Molecular Medicine at Case Western Reserve University School of Medicine. “These physician-scientists are driven by their commitment to patients for whom they have cared and we are committed to ensuring that our community can benefit from its creative talent.” 

Friday, September 23, 2016

University Hospitals appoints Sanjay Rajagopalan, MD, as new Chief of Cardiovascular Medicine

CLEVELAND – University Hospitals Cleveland Medical Center and UH Harrington Heart & Vascular Institute announce the appointment of Sanjay Rajagopalan, MD, as Chief of the Division of Cardiovascular Medicine effective September 26.
Dr. Rajagopalan is an exceptionally accomplished clinician scientist, with nearly three decades of experience leading translational research at elite academic medical centers. He is renowned worldwide for his pioneering work in cardiovascular magnetic resonance imaging, and is one of the nation’s top experts in the study of cholesterol, air pollution and other environmental factors on lung, heart and vascular diseases.
Before joining UH, he served as Co-Director of the Heart Center and Professor of Medicine since 2013 at the University of Maryland. He has also held academic positions at The Ohio State University, Mount Sinai School of Medicine, New York; University of Michigan, Ann Arbor; and Emory University School of Medicine, Atlanta.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.